Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating baricitinib to see if it can preserve beta-cell function in children and adults newly diagnosed with type 1 diabetes. This Phase 3 randomized, double-blind, placebo-controlled study includes participants aged 1 to under 36 years who have been recently diagnosed with type 1 diabetes. The study aims to understand the impact of baricitinib on insulin-producing cells to potentially support better diabetes management. Participants will be randomly assigned to receive either oral baricitinib or a placebo. The treatment period lasts up to 52 weeks, during which participants will take their assigned study medication regularly. The study compares the effects of baricitinib against placebo to assess preservation of beta-cell function and related outcomes. Throughout the approximately 60-week participation, individuals will undergo multiple assessments including measuring C-peptide levels, hemoglobin A1c, insulin use, hypoglycemic events, growth parameters, and quality of life surveys. Safety and drug levels will also be monitored. These evaluations help researchers determine how the study drug affects diabetes control and participant health over time.
Actively Recruiting
Researchers are evaluating orelabrutinib, a brain-penetrating BTK inhibitor, in patients with non-active Secondary Progressive Multiple Sclerosis SPMS. This phase 3, randomized, double-blind, multicenter study compares the effects and safety of orelabrutinib against placebo. About 990 participants will be enrolled globally and randomly assigned in a 21 ratio to receive either orelabrutinib or placebo. The study aims to assess disability progression and other neurological outcomes in this population. Participants will undergo a screening period of up to 4 weeks before starting treatment. The treatment period varies individually, lasting approximately 24 to 60 months, with a minimum of 12 months of double-blind treatment where participants receive either daily orelabrutinib orally or placebo. Participants showing confirmed disability progression at 24 weeks may continue in a 2-year open-label phase receiving orelabrutinib. After treatment ends, a 4-week safety follow-up is conducted unless participants join a long-term safety study where treatment continues. During the study, participants will be monitored regularly to track disability progression confirmed over 24 weeks and other outcomes including MRI lesions, relapse rates, and functional test results. Safety and tolerability of orelabrutinib are also assessed throughout up to about 120 weeks. All active participants will have a final study visit near the study end date, with additional safety follow-up visits when applicable. The total study duration can extend up to several years depending on individual participation and treatment phase.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of different doses of Corabotase also called IPN10200 for treating adults with upper limb spasticity. This study aims to understand how Corabotase affects the body and to determine which doses provide the best balance of safety and benefit. The trial involves adult participants aged 18 to 70 years who have spastic hemiparesis following stroke or traumatic brain injury and meet other specific health criteria. The study includes several groups receiving different doses of Corabotase, Dysport, or placebo as single injections into various upper limb muscles. Participants are assigned randomly to groups, with some in dose-escalation cohorts and others in fixed-dose groups. The injections are given once, and doses are carefully adjusted to assess safety and response. The trial uses a double-blind design, meaning neither participants nor researchers know who receives which treatment. Participants will be monitored over nine months with regular assessments including physical exams, vital signs, lab tests, and evaluations of muscle spasticity using the Modified Ashworth Scale. Researchers will track any side effects, antibody development, and changes in muscle tone and disability. Patient and physician impressions of treatment effects and pain levels will also be recorded. This long-term follow-up helps researchers understand how the treatments work and their safety over time.
Actively Recruiting
Researchers are evaluating remibrutinib for its effectiveness and safety in treating patients with secondary progressive multiple sclerosis SPMS. This Phase III, randomized, double-blind, placebo-controlled study involves about 1275 participants who meet specific criteria, including an SPMS diagnosis and disability progression. The trial is designed to provide detailed data on remibrutinibs impact compared to placebo, with a focus on disability progression and other neurological measures. Participants are randomly assigned to receive either remibrutinib or a matching placebo tablet during the Core Part of the study, which is event-driven and double-blind. Following this, there is an Extension Part where all participants receive open-label remibrutinib tablets. Treatment is oral and involves ongoing monitoring to assess long-term effects and safety. Throughout the study, participants will undergo regular assessments including disability evaluations using the Expanded Disability Status Scale EDSS, Timed 25-Foot Walk, 9-Hole Peg Test, and cognitive testing with the Symbol Digit Modalities Test SDMT. Brain imaging will be used to track lesion development and brain atrophy. Safety will be closely monitored by recording adverse events. The total participation may span up to approximately five years, covering both core and extension phases.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are conducting a national, prospective, multicenter observational pilot project in the Czech Republic to screen for Chronic Thromboembolic Pulmonary Hypertension CTEPH in patients who have experienced Acute Pulmonary Embolism APE. The study aims to develop and evaluate a standardized early detection procedure to improve patient outcomes and ensure cost-effective healthcare. This project involves multiple centers and targets patients after APE to facilitate timely diagnosis and treatment referral. Participants who have had APE will undergo a standardized screening protocol for early identification of CTEPH. If there is a risk identified during screening, patients will be referred promptly to specialized pulmonary hypertension centers for further management. This process includes implementing and testing a uniform screening algorithm and ensuring efficient patient flow from cardiologists to specialized treatment centers. During the study, participants will be assessed using this screening process within six months of enrollment. Key outcomes include the positive predictive value of the initial examination, rates of CTEPH detection, and the proportion of suspected cases attending follow-up at specialized centers. The study will monitor these factors to validate the screening protocols effectiveness and impact on patient care, with follow-up continuing up to six months after enrollment.
Actively Recruiting
Researchers are conducting a national, prospective, multicenter, non-interventional pilot project to screen for Hepatitis C virus HCV infection among people who inject drugs PWID in the Czech Republic. The main goal is to prepare, implement, and assess a method for early detection of Hepatitis C and to develop new procedures for integrating this screening into social health care systems. This project aims to help prevent further transmission of the virus by improving early diagnosis and care continuity.
Actively Recruiting
Researchers are studying relapsing multiple sclerosis RMS in this Phase 3b trial to compare the effects of switching from the drug ocrelizumab to remibrutinib versus continuing ocrelizumab treatment. The goal is to assess whether remibrutinib is similarly effective, safe, and tolerable for people living with RMS. This study is randomized, open-label, and conducted across multiple centers globally, including the USA. Participants will be randomly assigned to either switch to oral remibrutinib daily or continue their standard ocrelizumab treatment, which is given by infusion or injection. The study includes an initial Core Part lasting up to 24 months, during which efficacy and safety are closely monitored. After completing this phase, eligible participants may join an Extension Part of up to 24 months where all receive remibrutinib in an open-label format. During the study, participants will undergo regular assessments including MRI scans to measure new or enlarging brain lesions, neurological evaluations, and monitoring for adverse events. Researchers will track disease activity, safety, and tolerability throughout both study parts. The total participation time may be up to 48 months, providing long-term data on remibrutinib following ocrelizumab treatment.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the prevalence of oral infection with high-risk human papillomaviruses hrHPV in people aged 40 years and older in the Czech Republic. This study aims to better estimate the population at risk for oropharyngeal carcinoma and to develop effective screening and testing methods for early detection of this cancer. Participants will be recruited into two groups one group consists of healthy individuals visiting dental clinics who will complete a questionnaire and provide a self-collected gargling sample at the clinic the other group includes people identified from databases who will receive mailed kits to collect gargling samples at home. These samples will be tested for hrHPV using a certified diagnostic test. For those testing positive for oral hrHPV, blood samples will be collected regularly to check for circulating HPV DNA, and participants will be offered self-collection HPV tests of the urogenital area. During the study, researchers will assess the prevalence of oral and genital hrHPV infections, participation and sample return rates, hrHPV persistence, and plasma HPV DNA in positive individuals. Participants will complete questionnaires and provide samples, enabling close monitoring. The studys findings may support earlier diagnosis of oropharyngeal cancer. The total study duration includes follow-up over 24 months for primary outcomes.